Agilent Technologies, Inc. A
172.79
(0.05)
(0.03%)
as of 25 Sep
- Market cap
- $49.0B
- P/E
- 33.9×
Follow A
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Agilent Technologies, Inc. (A) Revenue growth
Agilent Technologies, Inc.'s revenue growth over the twelve months to 31 July 2026 was 8.60%, up 1.9 percentage points from fiscal 2025 (6.73%). Over the past ten years it has ranged from −4.73% (fiscal 2024) to 18.4% (fiscal 2021); the current reading is higher than 73% of that period. That is above the Diagnostics & Research industry median of 7.69% and in line with the Healthcare sector median of 8.26%.
Revenue growth, annual
Annual
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 6.73% | 11.46 |
| FY2024 | −4.73% | (4.51) |
| FY2023 | −0.22% | (8.59) |
| FY2022 | 8.37% | (9.99) |
| FY2021 | 18.4% | 14.95 |
| FY2020 | 3.41% | (1.66) |
| FY2019 | 5.07% | (4.81) |
| FY2018 | 9.88% | 3.45 |
| FY2017 | 6.43% | 2.37 |
| FY2016 | 4.06% | 4.31 |
Quarterly
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jul 2026 | 8.06% | (1.95) |
| Apr 2026 | 10.0% | 3.05 |
| Jan 2026 | 6.96% | (2.45) |
| Oct 2025 | 9.41% | (0.73) |
| 43 more quarters | Free account |
Against its own ten years
Low −4.73%
High 18.4%
Ten-year median
5.07%
Current reading's percentile
73
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| WAT Waters Corporation compare | 52.5% |
| GH Guardant Health, Inc. compare | 42.7% |
| NTRA Natera, Inc. compare | 37.8% |
| IDXX IDEXX Laboratories, Inc. compare | 12.8% |
| DGX Quest Diagnostics Incorporated compare | 9.87% |
| A Agilent Technologies, Inc. | 8.60% |
| IQV IQVIA Holdings Inc. compare | 8.17% |
| MTD Mettler-Toledo International, Inc. compare | 6.91% |
| ILMN Illumina, Inc. compare | 4.88% |
| Diagnostics & Research industry median | 7.69% |
| Healthcare sector median | 8.26% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on A
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- The full statement